Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

DCAT Value Chain Insights Bonus Coverage: From DCAT Week 2024: Supplier News Roundup 

What other DCAT Member Companies are making the news? A roundup of the latest developments from CDMOs/CMOs and other suppliers in drug-substance (small molecules & biologics) and drug-product development and manufacturing and packaging.

What other DCAT Member Companies are making the news? A roundup of the latest developments from CDMOs/CMOs and other suppliers in drug-substance (small molecules & biologics) and drug-product development and manufacturing and packaging. 

Companies making the news 
Here is a roundup of recent news announcements from DCAT Member Companies across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms), and packaging.  
 
See related stories and the companies making the news below:   

From DCAT Week 2024: Supplier News: Chemicals/Chemical API Manufacturing
Featuring news from Olon, Grace, PharmaBlock, Axplora, ChemCon, Suven Pharma and The Solubility Company. 

From DCAT Week 2024: Supplier News: Biologics Manufacturing
Featuring news from Siegfried and Solvias. 

From DCAT Week 2024: Supplier News: Formulation Development/Drug Product Manufacturing 
Featuring news from Alcami, Corealis Pharma, Curia, Delpharm and Grand River Aseptic Manufacturing. 

From DCAT Week 2024: Supplier News: End-to-End (Drug Substance and Drug Product)
Featuring news from Lonza and Mabion.  

From DCAT Week 2024: Supplier News: Packaging 
Featuring news from Adare Pharma Solutions and ApiJect 

Recent Feature Articles

Industry Roundtable: Small-Molecule APIs

By
What are the key issues shaping the market for small-molecule drugs and related trends in manufacturing? An industry roundtable of senior executives share their perspectives on what is driving the market.

What Trending: Biologic-Based Drugs

By
What were the biologic-based drugs approved by FDA’s Center for Drug Evaluation and Research in 2024? Which companies and products crossed the regulatory finish line and how do they fit in the market?

Upcoming DCAT European Conference: Expedition Pharma: Innovation from a Patient-First Perspective   

By
How is innovation inspiring and fueling the transformation of the bio/pharma industry?DCAT’s conference and networking event, Expedition Pharma: Innovation from a Patient-First Perspective, being held June 4–5, 2025, in Lugano, Switzerland, will provide key insights.  

The Bio/Pharma Majors’ Strategies & Products: Where Do Small-Molecule Drugs Rank?

By
How do small-molecule drugs rank in the strategy of the bio/pharmaceutical majors? What are the leading products from a revenue perspective, and what are key developments on a commercial and pipeline basis? DCAT Value Chain Insights looks at what may in store for 2025.